News

• Date
• Topic

• 2024-08-05
• NewNDA Submitted for TaiGen Influenza Antiviral TG-1000 in Mainland China

• 2024-04-18
• NewTaiGen Successfully Completes TG-1000 Phase III Study

• 2024-01-08
• TaiGen has completed the enrollment of TG-1000 phase III trial

• 2023-10-11
• TaiGen Enters Exclusive License Agreement with YSP

• 2023-03-22
• TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China

• 2022-08-28
• TaiGen Nemonoxacin Granted Marketing Authorization in Russia

• 2022-08-24
• TaiGen Successfully Completes TG-1000 Phase II Study

• 2022-02-07
• TaiGen has completed the enrollment of TG-1000 phase II trial

• 2021-03-30
• TaiGen Enters Transfer Agreement of Nemonoxacin with Zhejiang Medicine in China

• 2020-12-09
• TaiGen Initiated Phase II Trial of TG-1000